These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28631762)

  • 1. [Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk].
    Ambrosio G; De Ferrari GM; Federici M; Filardi PP
    G Ital Cardiol (Rome); 2017 Jun; 18(6):485-495. PubMed ID: 28631762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC; Borghi C; Consoli A; Volpe M
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
    Fisher M
    Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA; Marx N; Federici M
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
    Azim S; Baker WL; White WB
    Curr Cardiol Rep; 2014 Nov; 16(11):541. PubMed ID: 25303895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel antidiabetic drugs and cardiovascular complications].
    Pareek M; Mortensen MB; Løfgren B; Nielsen ML; Olsen MH; Andersen NH
    Ugeskr Laeger; 2018 Feb; 180(6):. PubMed ID: 29429477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
    Patil HR; Al Badarin FJ; Al Shami HA; Bhatti SK; Lavie CJ; Bell DS; O'Keefe JH
    Am J Cardiol; 2012 Sep; 110(6):826-33. PubMed ID: 22703861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
    White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
    Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.